Cabaletta Bio, Inc. – NASDAQ:CABA

Add to watchlist

$1.649

-0.64

-27.98%

Market closed

Open in about 3 hours

-72.21%

month

-72.21%

quarter

-90.20%

year

Market Cap	112.50M
Enterprise value	103.34M

P/E	-4.49
EV/Sales	N/A
EV/EBITDA	-1.34
Price/Sales	N/A
Price/Book	1.72
PEG ratio	0.12
EPS	-1.72

Revenue	N/A
EBITDA	-84.63M
Income	-76.86M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Cabaletta Bio, Inc. (NASDAQ:CABA): Profit margin
Jun 2023	0	-14.48M
Sep 2023	0	-16.44M
Dec 2023	4.01M	-20.88M	-520.85%
Mar 2024	0	-25.04M

Cabaletta Bio Financials Estimate

Q Y

Cabaletta Bio, Inc. (NASDAQ:CABA): Analyst Estimates
Sep 2025	0	-32.36M
Oct 2025	0	-33.40M
Dec 2025	0	-29.95M
Mar 2026	0	-32.18M

Analysts Price target
Financials & Ratios estimates

Cabaletta Bio, Inc. (NASDAQ:CABA): Payout ratio
Payout ratio	0%

Cabaletta Bio, Inc. (NASDAQ:CABA): Dividend Yield
2019	3.01%
2020
2021
2022
2023

Cabaletta Bio, Inc. (NASDAQ:CABA): Debt to assets
Jun 2023	184637000	10.49M	5.68%
Sep 2023	173287000	12.36M	7.13%
Dec 2023	253650000	17.45M	6.88%
Mar 2024	240457000	18.73M	7.79%

Cabaletta Bio, Inc. (NASDAQ:CABA): Cash Flow
Jun 2023	-11.88M	-48.14M	94.25M
Sep 2023	-12.60M	-65K	98K
Dec 2023	-16.44M	1.13M	93.04M
Mar 2024	-23.98M	-812K	6.85M

Cabaletta Bio alternative data

Cabaletta Bio, Inc. (NASDAQ:CABA): Employee count
Aug 2023	66
Sep 2023	77
Oct 2023	77
Nov 2023	77
Dec 2023	92
Jan 2024	92
Feb 2024	92
Mar 2024	101
Apr 2024	101
May 2024	101
Jun 2024	118
Jul 2024	118

Cabaletta Bio
Hedge Funds Holdings Q1 2023

85.87% -14.13%

of CABA is owned by hedge funds

29 -31

hedge funds hold CABA stock

1.84M -18.03M

shares is hold by hedge funds

CABA hedge funds holdings changes

Cabaletta Bio, Inc. (NASDAQ:CABA): Insider trades (number of shares)
Period	Buy	Sel
May 2023	0	22000
Jun 2023	0	11000
Jul 2023	0	11000
Aug 2023	0	11000
Sep 2023	0	11000
Oct 2023	0	11000
Nov 2023	0	11000
Dec 2023	0	11000
Jan 2024	0	11000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	19 Jan 2024	BINDER GWENDOLYN officer: See Rema..	Stock Option (Right to Buy)	11,000	$1.01	$11,110
Option	19 Jan 2024	BINDER GWENDOLYN officer: See Rema..	Common Stock	11,000	$1.01	$11,110
Sale	19 Jan 2024	BINDER GWENDOLYN officer: See Rema..	Common Stock	10,300	$19.54	$201,211
Sale	19 Jan 2024	BINDER GWENDOLYN officer: See Rema..	Common Stock	700	$20.33	$14,229
Option	19 Dec 2023	BINDER GWENDOLYN officer: See Rema..	Stock Option (Right to Buy)	11,000	$1.01	$11,110
Option	19 Dec 2023	BINDER GWENDOLYN officer: See Rema..	Common Stock	11,000	$1.01	$11,110
Sale	19 Dec 2023	BINDER GWENDOLYN officer: See Rema..	Common Stock	7,868	$21.76	$171,200
Sale	19 Dec 2023	BINDER GWENDOLYN officer: See Rema..	Common Stock	3,132	$22.22	$69,593
Option	20 Nov 2023	BINDER GWENDOLYN officer: See Rema..	Stock Option (Right to Buy)	11,000	$1.01	$11,110
Option	20 Nov 2023	BINDER GWENDOLYN officer: See Rema..	Common Stock	11,000	$1.01	$11,110

Cabaletta Bio
Executives

Insider	Age	Compensation
Dr. Steven A. Nichtberger (1961) Co-Founder, Chairman, Chief Executive Officer & Pres	64	$871,160
Dr. David J. Chang M.D., M.P.H. (1963) Chief Medical Officer	62	$638,630
Dr. Gwendolyn K. Binder (1975) Executive Vice President of Science & Technology	50	$625,130

Cabaletta Bio
Latest News

Tuesday, 22 October 2024
11:41	Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash	seekingalpha.com
Wednesday, 25 September 2024
16:30	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024	globenewswire.com
Wednesday, 28 August 2024
08:00	Cabaletta Bio to Participate in Upcoming Investor Conferences in September	globenewswire.com
Thursday, 8 August 2024
07:00	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Tuesday, 2 July 2024
08:00	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum	globenewswire.com
Friday, 28 June 2024
13:42	Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment	seekingalpha.com
Friday, 14 June 2024
02:00	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201	globenewswire.com
Wednesday, 15 May 2024
07:00	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 13 May 2024
08:00	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	GlobeNewsWire
Wednesday, 31 January 2024
02:53	Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward	Seeking Alpha
Sunday, 10 December 2023
02:44	Buy Cabaletta Bio's Promising SLE Treatment	Seeking Alpha
Tuesday, 28 November 2023
15:55	Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy	Market Watch
Monday, 30 October 2023
08:00	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November	GlobeNewsWire
Monday, 9 October 2023
11:17	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?	Zacks Investment Research
Monday, 25 September 2023
10:31	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'	Zacks Investment Research
Tuesday, 19 September 2023
08:00	Cabaletta Bio to Participate in Upcoming Investor Conferences in September	GlobeNewsWire
04:56	Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?	Seeking Alpha
Friday, 8 September 2023
10:32	Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable	Zacks Investment Research
Thursday, 31 August 2023
08:30	The 7 Most Promising Momentum Stocks to Own Now	InvestorPlace
Wednesday, 30 August 2023
08:00	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September	GlobeNewsWire
Wednesday, 23 August 2023
10:32	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why	Zacks Investment Research
Tuesday, 15 August 2023
15:27	Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?	Zacks Investment Research
Tuesday, 18 July 2023
14:58	Why Shares of Cabaletta Bio Are Up Tuesday	The Motley Fool
Wednesday, 21 June 2023
09:27	Why Is Cabaletta Bio (CABA) Stock Down 8% Today?	InvestorPlace
Sunday, 21 May 2023
08:20	TipRanks reveals the top 10 health care sector analysts of the past decade	CNBC
Tuesday, 2 May 2023
16:35	Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting	GlobeNewsWire
Thursday, 13 April 2023
16:30	Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference	GlobeNewsWire
Friday, 31 March 2023
21:02	Tech Stocks Are Surging	InvestorPlace
Tuesday, 28 February 2023
08:00	Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference	GlobeNewsWire
Monday, 6 February 2023
13:33	Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 11 Jun 2025

Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction
Seeking Alpha 6 Jun 2025

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Seeking Alpha 6 Jan 2025

Cabaletta Bio: Finding Optimism In Dire Straits
Seeking Alpha 28 Jun 2024

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Seeking Alpha 31 Jan 2024

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Seeking Alpha 11 Dec 2023

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology
Seeking Alpha 10 Dec 2023

Buy Cabaletta Bio's Promising SLE Treatment
Seeking Alpha 19 Sep 2023

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
Seeking Alpha 27 Apr 2023

Cabaletta Bio: Speculative Biotech With Opportunity
Seeking Alpha 15 Feb 2023

Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data

Frequently Asked Questions (FAQ)

What's the price of Cabaletta Bio stock today?

One share of Cabaletta Bio stock can currently be purchased for approximately $1.65.
When is Cabaletta Bio's next earnings date?

Unfortunately, Cabaletta Bio's (CABA) next earnings date is currently unknown.
Does Cabaletta Bio pay dividends?

No, Cabaletta Bio does not pay dividends.
How much money does Cabaletta Bio make?

Cabaletta Bio has a market capitalization of 112.50M.
What is Cabaletta Bio's stock symbol?

Cabaletta Bio, Inc. is traded on the NASDAQ under the ticker symbol "CABA".
What is Cabaletta Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Cabaletta Bio?

Shares of Cabaletta Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Cabaletta Bio's key executives?
Cabaletta Bio's management team includes the following people:
- Dr. Steven A. Nichtberger Co-Founder, Chairman, Chief Executive Officer & Pres(age: 64, pay: $871,160)
- Dr. David J. Chang M.D., M.P.H. Chief Medical Officer(age: 62, pay: $638,630)
- Dr. Gwendolyn K. Binder Executive Vice President of Science & Technology(age: 50, pay: $625,130)
Is Cabaletta Bio founder-led company?

Yes, Cabaletta Bio is a company led by its founder Dr. Steven A. Nichtberger.
How many employees does Cabaletta Bio have?

As Jul 2024, Cabaletta Bio employs 118 workers, which is 17% more then previous quarter.
When Cabaletta Bio went public?

Cabaletta Bio, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.
What is Cabaletta Bio's official website?

The official website for Cabaletta Bio is cabalettabio.com.
Where are Cabaletta Bio's headquarters?

Cabaletta Bio is headquartered at 2929 Arch Street, Philadelphia, PA.
How can i contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 Arch Street, Philadelphia, PA and company can be reached via phone at +267 7593100.

Cabaletta Bio, Inc.

cabalettabio.com

Exchange:

NASDAQ

Full time employees:

136

Industry:

Biotechnology

Sector:

Healthcare

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

+267 7593100

2929 Arch Street
Philadelphia, PA 19104

CIK: 0001759138
ISIN: US12674W1099
CUSIP: 12674W109